share_log

Conmed Analyst Ratings

Conmed Analyst Ratings

Conmed 分析師評級
Benzinga ·  2023/07/27 04:34
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/27/2023 14.98% Keybanc $131 → $141 Maintains Overweight
07/24/2023 13.35% Needham → $139 Reiterates Buy → Buy
06/05/2023 13.35% Needham $135 → $139 Maintains Buy
05/22/2023 14.16% CL King → $140 Initiates Coverage On → Buy
04/27/2023 6.01% Stifel $118 → $130 Maintains Buy
04/27/2023 4.38% Piper Sandler $118 → $128 Maintains Overweight
04/27/2023 -2.96% Wells Fargo $96 → $119 Maintains Equal-Weight
04/27/2023 10.09% Needham $122 → $135 Maintains Buy
04/27/2023 6.83% Keybanc $124 → $131 Maintains Overweight
03/27/2023 1.12% Keybanc → $124 Upgrades Sector Weight → Overweight
02/03/2023 -3.78% Piper Sandler $108 → $118 Maintains Overweight
02/03/2023 -0.51% Needham $106 → $122 Maintains Buy
11/15/2022 -13.56% Needham $90 → $106 Maintains Buy
10/14/2022 -26.61% Needham $123 → $90 Maintains Buy
10/12/2022 -30.69% Jefferies → $85 Initiates Coverage On → Hold
08/02/2022 0.3% Needham $127 → $123 Maintains Buy
07/28/2022 -3.78% Piper Sandler $160 → $118 Maintains Overweight
07/28/2022 3.56% Needham $155 → $127 Maintains Buy
06/23/2022 -10.3% Stifel $160 → $110 Maintains Buy
05/05/2022 26.4% Needham $150 → $155 Maintains Buy
01/21/2022 22.32% Needham $158 → $150 Maintains Buy
10/28/2021 28.84% Needham $150 → $158 Maintains Buy
10/06/2021 22.32% Needham → $150 Upgrades Hold → Buy
07/15/2021 30.47% UBS → $160 Initiates Coverage On → Buy
05/25/2021 42.71% Barclays → $175 Initiates Coverage On → Overweight
04/29/2021 30.47% Piper Sandler $145 → $160 Maintains Overweight
07/30/2020 -22.53% Piper Sandler $90 → $95 Maintains Overweight
07/30/2020 -18.45% Stifel $82 → $100 Maintains Buy
07/30/2020 -24.98% SVB Leerink $82 → $92 Maintains Market Perform
04/30/2020 -33.13% Stifel $65 → $82 Maintains Buy
04/23/2020 -38.02% JP Morgan $136 → $76 Maintains Overweight
11/26/2019 — Needham Downgrades Buy → Hold
11/12/2019 10.9% JP Morgan → $136 Initiates Coverage On → Overweight
10/31/2019 -3.78% Stifel $99 → $118 Maintains Buy
08/22/2019 -10.3% Piper Sandler $88 → $110 Upgrades Neutral → Overweight
08/01/2019 -19.27% Stifel $97 → $99 Maintains Buy
04/18/2019 -22.53% Stifel → $95 Initiates Coverage On → Buy
04/15/2019 -24.98% Barclays $85 → $92 Maintains Overweight
02/19/2019 -30.69% Barclays → $85 Reinstates → Overweight
10/16/2018 -36.39% Barclays → $78 Initiates Coverage On → Equal-Weight
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
07/27/2023 14.98% KeyBanc $131→$141 維護 超重
07/24/2023 13.35% 李約瑟 →$139 重申 購買→購買
06/05/2023 13.35% 李約瑟 $135→$139 維護 買
2023年05月22日 14.16% CL國王 →$140 開始承保 →購買
04/27/2023 6.01% Stifel $118→$130 維護 買
04/27/2023 4.38% 派珀·桑德勒 $118→$128 維護 超重
04/27/2023 -2.96% 富國銀行 $96→$119 維護 等重
04/27/2023 10.09% 李約瑟 $122→$135 維護 買
04/27/2023 6.83% KeyBanc $124→$131 維護 超重
03/27/2023 1.12% KeyBanc →$124 升級 行業權重→超配
02/03/2023 -3.78% 派珀·桑德勒 $108→$118 維護 超重
02/03/2023 -0.51% 李約瑟 $106→$122 維護 買
2022年11月15日 -13.56% 李約瑟 $90→$106 維護 買
10/14/2022 -26.61% 李約瑟 $123→$90 維護 買
10/12/2022 -30.69% 傑富瑞 →$85 開始承保 →保留
08/02/2022 0.3% 李約瑟 $127→$123 維護 買
07/28/2022 -3.78% 派珀·桑德勒 $160→$118 維護 超重
07/28/2022 3.56% 李約瑟 $155→$127 維護 買
2022/06/23 -10.3% Stifel $160→$110 維護 買
05/05/2022 26.4% 李約瑟 $150→$155 維護 買
2022年01月21日 22.32% 李約瑟 $158→$150 維護 買
10/28/2021 28.84% 李約瑟 $150→$158 維護 買
10/06/2021 22.32% 李約瑟 →$150 升級 持有→購買
07/15/2021 30.47% 瑞銀集團 →$160 開始承保 →購買
2021/05/25 42.71% 巴克萊 →$175 開始承保 →超重
04/29/2021 30.47% 派珀·桑德勒 $145→$160 維護 超重
07/30/2020 -22.53% 派珀·桑德勒 $90→$95 維護 超重
07/30/2020 -18.45% Stifel $82→$100 維護 買
07/30/2020 -24.98% SVB Leerink $82→$92 維護 市場表現
04/30/2020 -33.13% Stifel $65→$82 維護 買
04/23/2020 -38.02% 摩根大通 $136→$76 維護 超重
2019年11月26日 - 李約瑟 評級下調 購買→Hold
2019年11月12日 10.9% 摩根大通 →$136 開始承保 →超重
2019年10月31日 -3.78% Stifel $99→$118 維護 買
2019年08月22日 -10.3% 派珀·桑德勒 $88→$110 升級 中性→超重
2019年08月01日 -19.27% Stifel $97→$99 維護 買
2019/04/18 -22.53% Stifel →$95 開始承保 →購買
2019年04月15日 -24.98% 巴克萊 $85→$92 維護 超重
2019年02月19日 -30.69% 巴克萊 →$85 恢復 →超重
2018年10月16日 -36.39% 巴克萊 →$78 開始承保 →等重

What is the target price for Conmed (CNMD)?

康美德(CNMD)的目標價是多少？

The latest price target for Conmed (NYSE: CNMD) was reported by Keybanc on July 27, 2023. The analyst firm set a price target for $141.00 expecting CNMD to rise to within 12 months (a possible 14.98% upside). 18 analyst firms have reported ratings in the last year.

Keybanc於2023年7月27日報道了Conmed(紐約證券交易所代碼：CNMD)的最新目標價。這家分析公司將目標價定為141.00美元，預計CNMD將在12個月內上漲至14.98%。去年有18家分析公司公佈了評級。

What is the most recent analyst rating for Conmed (CNMD)?

康美德(CNMD)的最新分析師評級是多少？

The latest analyst rating for Conmed (NYSE: CNMD) was provided by Keybanc, and Conmed maintained their overweight rating.

Conmed(紐約證券交易所代碼：CNMD)的最新分析師評級由Keybanc提供，Conmed維持其增持評級。

When is the next analyst rating going to be posted or updated for Conmed (CNMD)?

Conmed(CNMD)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.

分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Conmed的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Conmed的上一次評級是在2023年7月27日提交的，所以你應該預計下一次評級將在2024年7月27日左右提供。

Is the Analyst Rating Conmed (CNMD) correct?

分析師評級Conmed(CNMD)正確嗎？

While ratings are subjective and will change, the latest Conmed (CNMD) rating was a maintained with a price target of $131.00 to $141.00. The current price Conmed (CNMD) is trading at is $122.63, which is out of the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但康美德(Conmed)最新的評級維持不變，目標價在131.00美元至141.00美元之間。康美德目前的交易價格為122.63美元，超出了分析師的預測區間。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論